Metastatic cancer

What it is

Metastatic cancer is cancer that has spread from its original site to distant parts of the body, which is stage IV for many solid tumours. The key point is that the cancer keeps the identity of where it started: for example, breast cancer that spreads to bone is still metastatic breast cancer, not bone cancer. Doctors may also call this metastatic disease, metastasis, or metastases. In many cancers, metastasis is the main reason cancer becomes life-threatening because it can impair the function of organs such as the liver, lungs, brain, or bones.

Metastasis is different from local spread or regional spread. Local spread means the tumour has grown into nearby tissue. Regional spread usually means nearby lymph nodes are involved. Metastatic disease means cancer cells have established growth in a distant organ or tissue.

A simple way to think about it is:

Term	What it means
Localised cancer	Limited to the organ where it started
Regional cancer	Spread to nearby tissues or lymph nodes
Metastatic cancer	Spread to distant organs or distant lymph nodes

Common sites of metastasis include the bone, liver, lung, and brain, but the pattern depends on the original cancer type. For example, prostate cancer often spreads to bone, while colorectal cancer commonly spreads to the liver.

How it works

Metastasis is a multistep biological process, and most cancer cells that leave the primary tumour do not successfully form a new tumour. To metastasise, cancer cells usually have to:

1. Break away from the primary tumour.
2. Invade nearby tissue.
3. Enter blood vessels or lymphatic channels.
4. Survive the stress of travelling in the circulation.
5. Exit into a distant organ.
6. Adapt to that new environment and grow.

This last step is especially important. A distant organ may be hostile to cancer cells because of immune defenses, oxidative stress, and lack of supportive growth signals. Some disseminated cancer cells can remain dormant for months or years before growing enough to be seen on scans. This helps explain why some people develop recurrence long after treatment of the original cancer.

Metastatic spread is not random. Different cancers show preferences for certain organs because of blood flow patterns, molecular signals, and the local tissue environment. Researchers sometimes describe this as the interaction between the "seed" and the "soil": the cancer cell is the seed, and the distant organ environment is the soil.

Diagnosis / how it's measured

Metastatic cancer is diagnosed using a combination of symptoms, examination, imaging, pathology, and sometimes blood tests. Imaging is often the first clue.

Common tests include:

• CT scan: often used to look at chest, abdomen, and pelvis
• MRI: especially useful for brain, spine, liver, and some soft tissues
• PET-CT: can help detect active cancer in many tumour types
• Bone scan: sometimes used when bone metastases are suspected
• Biopsy: may confirm that a distant lesion is metastatic cancer and identify its origin

Pathology and biomarker testing are often important because treatment depends on the primary cancer type and its molecular features. For example, metastatic lung cancer may be tested for EGFR, ALK, ROS1, KRAS, PD-L1, and other markers. Metastatic breast cancer may be retested for ER, PR, and HER2 because these can differ from the original tumour.

Staging systems vary by cancer type, but metastatic disease is commonly classified as M1 in the TNM system. In many solid tumours, this corresponds to stage IV, though there are exceptions. Blood tests such as liver function tests, calcium, alkaline phosphatase, or tumour markers may support assessment, but they do not by themselves prove metastasis.

In India, the work-up usually follows the same principles used internationally, though the exact imaging and biomarker panels may depend on the cancer centre, availability, and cost. Multidisciplinary tumour boards are often used in larger centres to plan treatment.

Evidence and uses

The presence of metastasis changes treatment goals and options. For many cancers, metastatic disease is treatable but not usually curable, although there are important exceptions. Treatment may aim to prolong life, control symptoms, shrink tumours, delay progression, and maintain quality of life.

Main treatment approaches include:

Approach	Typical role in metastatic cancer
Systemic therapy	Treats cancer throughout the body; includes chemotherapy, hormone therapy, targeted therapy, immunotherapy
Surgery	Used in selected cases, such as symptom relief or limited metastases
Radiation therapy	Helps control pain, bleeding, brain metastases, or specific lesions
Ablative/local therapies	Includes radiofrequency ablation, embolisation, stereotactic radiotherapy in selected patients
Supportive and palliative care	Manages pain, fatigue, breathlessness, nutrition, and other symptoms

A special situation is oligometastatic disease, where there are only a small number of metastatic sites. This is considered an intermediate state between localised and widely metastatic cancer. In selected patients, aggressive local treatment to all known sites, such as surgery or stereotactic body radiotherapy, may improve disease control and sometimes survival. One well-known example is colorectal cancer with liver metastases: surgical removal of liver metastases can be curative in a minority of patients, with reviews citing cure in about 20% of selected cases.

Even when cure is not possible, treatment can still be meaningful. Modern targeted therapies and immunotherapies have improved outcomes in some metastatic cancers, but benefit depends heavily on tumour biology. For instance, some metastatic melanoma, lung cancer, breast cancer, and prostate cancer subtypes now have longer survival than was typical in the past.

Palliative care is not the same as end-of-life care. It can and should be introduced early to help with symptoms, treatment side effects, emotional stress, and planning.

When to see a clinician

Anyone with a current or past cancer diagnosis should contact their cancer team promptly if they develop symptoms that could suggest metastasis or recurrence. These symptoms depend on the organ involved.

Examples include:

• New or worsening bone pain, especially at night
• Unexplained weight loss or marked fatigue
• Persistent cough or shortness of breath
• New headaches, seizures, weakness, or confusion
• Abdominal swelling, jaundice, or persistent nausea
• Severe back pain, numbness, or bladder/bowel changes, which can signal spinal cord compression

These symptoms do not always mean metastatic cancer, but they should be assessed without delay. Emergency evaluation is needed for red-flag problems such as sudden weakness, seizures, severe breathlessness, confusion, or loss of bladder or bowel control.

Limitations and open questions

Metastatic cancer is not one disease. Its behaviour varies widely by cancer type, molecular subtype, organ involved, and response to treatment. Two people with the same primary cancer can have very different outcomes.

There are also limits to current testing. Imaging may miss very small deposits, and dormant micrometastatic disease can exist before it becomes clinically visible. Researchers are studying circulating tumour DNA, circulating tumour cells, and other biomarkers to detect relapse earlier, but these tools are not yet definitive for every cancer or every clinical decision.

The biology of dormancy, treatment resistance, and organ-specific spread remains an active research area. Evidence is strongest for established imaging, pathology, and standard systemic treatments. Evidence for exactly who benefits most from metastasis-directed treatment in oligometastatic disease is still evolving and differs by tumour type.

For patients and families, the most useful next step is usually to ask three practical questions: Where did the cancer start? Where has it spread? What is the goal of treatment now? Those answers guide prognosis, treatment choices, and supportive care planning.